Firebrick Pharma

21/01/2026

Big News from Firebrick Pharma (ASX:FRE) 🚀 We are thrilled to announce that our new product—Nasodine® Throat Spray—has officially launched in Singapore! 🇸🇬 Following successful manufacturing in Australia and shipment earlier this month, this launch marks a significant milestone in our international expansion. 🌍

Why it matters:

✅ Comprehensive care: Nasodine Throat Spray (1% povidone-iodine) complements our existing Nasal Spray, providing dual "nasal and oral" defence against the germs that cause colds and flu.

✅ Strategic rollout: Partnering with Innorini Life Sciences, the initial 6-month focus will be on hospitals and healthcare professionals (HCPs) before hitting retail shelves in Singapore.

✅ The convenience of the throat spray should a major benefit in the Singapore market; it’s perfect for travel, commuting, and other on-the-go uses.

30/10/2025

Firebrick Pharma (ASX:FRE) is excited to confirm the commencement of manufacturing of our new Nasodine® Throat Spray! 🎉Set for export in November 2025, this marks a significant expansion of our Nasodine brand. Available in a convenient throat spray form, Nasodine Throat Spray is very distinct from other throat gargles already available in many markets. Learn more about our innovative sore throat solution here:

https://wcsecure.weblink.com.au/pdf/FRE/03016301.pdf

11/06/2025

📹 WATCH: Important new plans for Firebrick revealed 👀 Executive Chairman Peter Molloy recently joined HotCopper's "The Market Link" to unpack the significance of our latest announcement and our renewed focus on the US market! 🚀 To stay on top of the exciting developments happening at Firebrick Pharma, this webinar is a must-watch https://cdn.jwplayer.com/previews/l0Av6Ae8-dN4sOW5Y

10/06/2025

BIG NEWS FOR NASODINE! Newly published Phase 3 clinical trial data on Nasodine® Nasal Spray concludes: “Nasodine is an effective and clinically meaningful treatment for the common cold.” “It [Nasodine] is the first intervention in URTI that targets the microbial cause of the illness.” ”The current study demonstrated for the first time that targeting the viral load in the nose with a 0.5% PVP-I nasal spray (Nasodine) has a beneficial effect on cold severity and especially functional impairment.”

Read the paper here: https://lnkd.in/gkdMujV2

Learn more about Nasodine: nasodine-sg.com

12/02/2025

We are thrilled to announce the launch of Nasodine in Fiji and the South Pacific! 🤝 The exclusive agreement is with Makans Ltd, the largest pharmaceutical wholesaler in the region and the license agreement has similar terms to the Philippines agreement with no marketing costs to Firebrick. ✅

The South Pacific is a relatively small market (around 2 million people), so why is this deal important?

1. It shows that there are more markets where we can introduce Nasodine without undue regulatory delays ✅

2. It shows that market-savvy pharmaceutical partners see the potential in Nasodine ✅

3. Like the Philippines agreement with SV More, Firebrick simply receives license fees with no marketing costs ✅

4. It represents another market where people will enjoy the protective benefits of Nasodine ✅

30/10/2024

We are excited to launch a new healthcare professional (HCP) marketing campaign for Nasodine in Singapore! The campaign starts tomorrow (1 November) under an agreement with Innorini Life Sciences. 🤝 Innorini’s medical reps will now promote and sell Nasodine to GPs and hospitals, with a focus on the top 400 dispensing GPs in the first few months.

They have a target of at least 140 calls per month and they are optimistic about the prospects for Nasodine and excited to have such a breakthrough product to promote and sell.

Read more https://loom.ly/nSeTzdc

02/10/2024

📹 WATCH: Executive Chairman Peter Molloy yesterday presented a webinar outlining the new Firebrick strategy. If you missed this presentation, you can click the link to watch it here. The webinar also includes an interesting Q&A section at the end.

Watch here: https://bit.ly/47R6okK

09/09/2024

We have two big announcements! 🔥 We're thrilled to announce that the former head of Johnson & Johnson Consumer Health in APAC, Keith Shortall, has been hired as a consultant to drive distribution and partnering of Nasodine in Singapore and throughout Asia. 💪 The other big news is that we have filed for approval of Nasodine as a nasal antiseptic in Europe!

Read more: https://loom.ly/rLe3KOg and here https://loom.ly/NWpK6JM

06/09/2024

We're excited to share Executive Chairman Dr Peter Molloy's latest interview with !🔥 Dr Molloy outlined the company’s business model for Nasodine Nasal Spray which is already available in the US and Singapore, and will soon be launched in the Philippines, under Firebrick’s partnership with SV More.

The Philippines deal highlights the future strategy for the company in all markets, which is to secure committed partnerships in each country or region, and manufacture Nasodine in-country to facilitate local registration and reduce costs.

Watch here: https://loom.ly/mHDXYns

Firebrick Pharma has capped a successful year launching its product Nasodine Nasal Spray in the US, Singapore and will shortly launch in the Philippines in p

15/08/2024

We are very excited to announce an agreement which will allow Nasodine® Nasal Spray to be launched as an OTC into the Philippines (a market of 119 million people) without any additional clinical studies!! 🔥

This is very exciting:

✅ The Philippines is a large pharmaceutical market with a population 20 times that of Singapore.

✅ SV More will use its professional marketing team to drive Nasodine sales through drugstores, and build strong consumer franchise based on pharmacist and doctor recommendation.

✅ SV More will be responsible for managing local manufacturing in the Philippines as well as the working capital commitment; in Singapore, Firebrick currently bears that cost.

20/06/2024

Nasodine has been featured on ASX Briefs!🎙️The interview provided an opportunity to discuss our plans for Nasodine in the US and Singapore. Listen to the full episode here.

https://loom.ly/GPp02Rc

19/06/2024

WATCH 📹: We were thrilled to be featured on Grafa this week, where we discussed the growing povidone-iodine market in the US and exciting opportunity for new PI products! Watch a snippet of the interview here.

https://youtu.be/0BFMqxjl6YQ

Dr Peter Molloy discusses the exciting and growing opportunity for Povidone-Iodine products in the US. He speaks to Heidi Cuthbert from Grafa about the recen...